Medicina
Departamento
Università di Perugia
Perugia, ItaliaPublicaciones en colaboración con investigadores/as de Università di Perugia (38)
2023
-
Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive
Internal and Emergency Medicine, Vol. 18, Núm. 6, pp. 1619-1634
-
Bleeding risk with concomitant administration of VEGF-TKIs and anticoagulant agents
Seminars in Oncology, Vol. 50, Núm. 3-5, pp. 67-70
-
Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies
Rheumatology (United Kingdom), Vol. 62, Núm. 1, pp. 243-255
-
Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism
European Journal of Internal Medicine, Vol. 112, pp. 29-36
-
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL
American Journal of Hematology, Vol. 98, Núm. 12, pp. 1856-1868
2022
-
Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer
Thrombosis and Haemostasis, Vol. 122, Núm. 5, pp. 796-807
-
Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain
Journal of Medical Economics, Vol. 25, Núm. 1, pp. 840-847
-
Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial
Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661
-
Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study
European Journal of Cancer, Vol. 165, pp. 136-145
-
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study
The Lancet, Vol. 399, Núm. 10333, pp. 1383-1390
-
Venous thromboembolism risk, prophylaxis and management in cancer patients with COVID-19: An unmet medical need
Thrombosis Update, Vol. 6
2021
-
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
Leukemia, Vol. 35, Núm. 12, pp. 3444-3454
-
Corrigendum to "Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 32 (2021) 439-451
Annals of oncology : official journal of the European Society for Medical Oncology
-
Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism
European Journal of Cancer, Vol. 148, pp. 371-381
-
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
Annals of Oncology, Vol. 32, Núm. 4, pp. 439-451
-
Multinational evaluation of the BioFire® FilmArray® Pneumonia plus Panel as compared to standard of care testing
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 40, Núm. 8, pp. 1609-1622
-
Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT
Bone Marrow Transplantation, Vol. 56, Núm. 8, pp. 1900-1907
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2020
-
Apixaban for the treatment of venous thromboembolism associated with cancer
New England Journal of Medicine, Vol. 382, Núm. 17, pp. 1599-1607
-
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
Leukemia, Vol. 34, Núm. 9, pp. 2354-2363